Moradec LLC was founded in 2012 by Helen (Hongyuan) Mao, PhD, with the main goal of providing novel research tools for speedy and economic antibody-drug conjugate discovery. Dr. Mao has over 14 years of research and development experience in industry, including major pharmaceutical companies, medium and small biotechnology companies. She was most recently as the Chief Scientific Officer at Fabrus, key for developing the Fabrus Arrayed Antibody Screening Technology. In addition to her extensive antibody optimization expertise, she has accumulated substantial knowledge in the epidermal growth factor receptors-based antibody therapeutics. Prior to Fabrus, Dr. Mao headed the protein purification group for Antibody Development at Biosite (now Alere), a leading diagnostic company with phage display platform technology for developing diagnostic antibodies. At Ansata Therapeutics, Dr. Mao invented the novel sortase-based enzymatic protein conjugation method, which has since gained worldwide research applications for cell-surface labeling, protein arrays, NMR, and protein-drug conjugation, etc. Dr. Mao conducted her postdoctoral research at the Abbott Laboratory and Genomic Institute of the Novartis Research Foundation (GNF). She received her PhD in Biochemistry from Massachusetts Institute of Technology and BS in Chemistry from Peking University.